Drug facts
BrandDefinity (Perflutren)
No generic perflutren is approved; the latest Definity patent or exclusivity in the Orange Book runs to 05/04/2037.
Definity was first approved by the FDA on 07/31/2001 under NDA 021064; the application holder is Lantheus Medical Imaging Inc.
Holder Lantheus Medical Imaging IncApplication NDA 021064Approved 07/31/2001
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
3,838days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved07/31/2001
Last patent05/04/2037
20022007201220172022202720322037
- Latest patent
- 05/04/2037Definity Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Definity profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Lantheus Medical Imaging Inc Orange Book
- Application
- NDA 021064 Orange Book
- First approved
- 07/31/2001 Orange Book
- Dosage forms
- injectable
- Routes
- intravenous
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.